Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX Alternated With mGnabP in Untreated Metastatic Pancreatic Cancer
NCT04672005Phase 2Active, not recruiting
- Start
- Jan 2021
- Primary completion
- Sep 2024
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, folinic acid, irinotecan, fluorouracil, gemcitabine and 1 more in pancreatic adenocarcinoma (PDAC). Primary endpoint: Time to Treatment Failure at 24 weeks. Started Jan 2021; status: active, not recruiting.
02
Drugs
oxaliplatinfolinic acidirinotecanfluorouracilgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04672005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672005.